Overview of Orthocell's (ASX: OCC)

Orthocell Limited (ASX: OCC) is a regenerative medicine company focused on addressing unmet clinical needs in musculoskeletal and peripheral nerve repair. Listed on the Australian Securities Exchange under the ticker OCC and trading on the US OTC market as ORHHF, the company develops products based on a proprietary collagen platform inspired by the natural architecture of biological tissue.

Orthocell was co-founded by Chief Scientific Officer Professor Ming Hao Zheng, who drew inspiration from the structure of sea sponges to create a collagen medical device that mimics natural tissue architecture. The company’s scientific philosophy centres on harnessing the body’s own biology to regenerate damaged tissue rather than relying on synthetic implants. Its revenue model combines direct commercialisation with specialist distributor networks across Australia, the US, the UK, and other international markets.

Product Portfolio

Orthocell's commercial product suite spans multiple injury categories:

Product	Category	Indication
Remplir™	Biological device	Peripheral nerve repair (collagen wrap)
Striate+™	Collagen membrane	Guided bone & tissue regeneration in dental surgery
OrthoACI	Cell therapy implant	Articular cartilage defects (knee & ankle)
Ortho-ATI	Injectable cell therapy	Chronic tendon injuries

Remplir™ is the company's flagship product — a collagen scaffold that wraps around a damaged nerve to support regeneration. OrthoACI is an autologous therapy that uses the patient's own chondrocytes to regenerate damaged cartilage.

Recent Milestones & Future Plans

Orthocell's growth strategy is strongly focused on US commercialisation and global regulatory expansion:

· US Military & VA access (April 2026): Orthocell secured approval to sell Remplir™ across 51 US Department of Defence hospitals and 170 Veterans Affairs medical centres, a landmark breakthrough that sent the share price up 22%.

· US VAC approvals: The company has secured 32 Value Analysis Committee (VAC) approvals, granting access to over 115 hospitals, with 57 additional applications pending as of March 2026.

· US distributor network: Currently spans 17 states, targeting a 700,000+ nerve repair procedure market valued at $3.2 billion globally.

· UK expansion: LEDA Orthopaedics appointed as exclusive UK distributor for Remplir™; European and UK regulatory submissions filed in December 2025, with approvals anticipated in Q3 2026.

· Canada & Asia-Pacific: Regulatory approvals secured in Singapore, Hong Kong, Thailand, and Canada.

· Profitability target: Management expects to reach profitability within the current cash runway period, driven by US market penetration.

Orthocell's ambition is to capture a 20% share of the $3.2 billion global nerve repair market, with Remplir™ as its flagship growth driver.

Why Is the Market Cautious? Key Reasons Behind the Downward Trend in Orthocell Limited (ASX: OCC)

Here is a comprehensive breakdown of the most important reasons behind the downward trend in OCC’s shares:

Revenue pace

A key concern is that March-quarter revenue was flat versus the prior quarter, even though it was up 45% year on year. Bell Potter also noted that calendar Q1 is usually seasonally softer and that repeat ordering can lag while first-use surgeons assess product performance in their own cases, which reinforces the view that commercial traction may take time to build.

Profitability gap

Orthocell is still loss-making, which keeps pressure on management to prove that revenue growth can eventually cover operating spend. H1 FY26 revenue was A$5.4 million, but the company still posted a net loss of A$5.2 million, and the trailing 12-month net loss was A$12.5 million with EPS still negative. For many investors, that means the story remains execution-led rather than earnings-backed.

Flat Revenue Growth & Weak US Traction

The March 2026 quarterly report — which triggered a 7% single-day crash — revealed that total revenue of $3.2 million was flat quarter-on-quarter, despite being up 45% year-on-year. US Remplir sales came in at just $300k for the full quarter. Bell Potter also flagged a lag in repeat ordering from first-use surgeons still evaluating product performance, suggesting the US commercialisation ramp is slower than the market expected.

Dilutive Capital Raising

In October 2025, Orthocell raised $30 million via an institutional placement at a 9.1% discount, which directly diluted existing shareholders and caused a 7% single-day drop at the time. For a pre-profitability company still burning cash, repeated capital raises are viewed negatively by the market as they signal the company cannot yet self-fund its growth.

Rollout risk

The company’s US rollout is encouraging, but the market appears to be discounting the fact that adoption curves in medtech are rarely linear. Bell Potter said the military hospital access win is a meaningful de-risking event, yet also said uptake across those channels will take time and that the greater earnings contribution is likely to come in later years. Orthocell’s own March-quarter commentary pointed to growing surgeon adoption and stronger US momentum, but that still leaves investors waiting for clearer evidence of sustained scale.

Important Disclaimer: You’re reading a free article that offers general opinions and insights. For exclusive, in-depth research, timely high-conviction investment ideas, and actionable trade signals designed to help you stay ahead, join Proactive Equities today by opening a Free Trial Account now! (No Credit Card Required)

Technical Analysis of Orthocell Limited (ASX: OCC)

Source: Trading view

Since early 2025, OCC has traded within a downward-sloping channel, reflecting a clear bearish trend with lower highs and lower lows. The current price of A$0.870 is in the lower half of the channel, indicating ongoing selling pressure. Year-to-date, the stock has fallen about 21.66%.

Price action

The dominant structure is a falling channel, which means the broader trend is still down until price can break and hold above the upper channel boundary.

Price levels

· Support 1 is around 0.86–0.87, which is the most immediate level price is testing now.

· Support 2 is around 0.70–0.72, matching the recent low area and lower part of the broader channel.

· Resistance is around 1.08–1.12, and above that the upper descending channel line near roughly 1.10–1.15 remains the bigger breakout barrier.

Stop loss

Considering the descending channel line and the second support level, the stop-loss zone is approximately between 0.55 and 0.60. Should the price fall into this area, accompanied by consolidation and a rise in trading volume, it would signal a more severe technical breakdown.

RSI

· The RSI is sitting around 49.56 on the chart, which is close to neutral momentum.

· That reading says the stock is neither overbought nor oversold at the moment, so momentum is balanced but not strong enough yet to confirm a bullish trend change.

· TThe recent RSI pullback from above 60 toward 50 also fits the idea that upside momentum cooled after the rejection near resistance.

Volume

Volume has generally been stronger during sharp moves and weaker during quieter consolidation phases, which suggests participation rises mainly when the price becomes more directional. The recent rebound was accompanied by some increase in turnover, but the move did not sustain with strong follow-through buying once the price approached resistance. That volume profile implies buyers were active on the bounce, though not yet dominant enough to confirm a lasting breakout.

FAQs about Orthocell Limited (ASX: OCC)

1- What is the key long-term question for investors?

The key long-term question is whether Orthocell can turn promising products and approvals into durable, repeatable global sales growth. Investors will be watching whether the company can build market share, defend its competitive position, and broaden its product footprint over time.

2- Who are Orthocell’s competitors in nerve repair?

Orthocell competes in the broader nerve repair and regeneration market alongside players such as AxoGen and Integra LifeSciences. These companies operate in adjacent surgical repair categories, although Orthocell’s positioning emphasises its collagen-based regenerative approach and handling benefits.

3- What are the main risks for Orthocell investors?

The main risks include slower-than-expected product adoption, execution challenges in the U.S. rollout, regulatory delays in new markets, and the possibility that commercial revenue growth does not meet expectations. As with many growth-stage medtech companies, sentiment can weaken quickly if milestones are missed.